Suven Life Sciences has suffered heavy setback during the fourth quarter ended March 2015 due to lower sales. Its net profit declined by 47.7 per cent to Rs.16.95 crore from Rs.32.40 crore in the corresponding period of last year as its net sales declined by 15.4 per cent to Rs.110.66 crore from Rs.130.80 crore. Its EBIDTA also declined by 41.8 per cent to Rs.28.31 crore from Rs.48.64 crore. The company's R&D expenditure improved by 9.8 per cent to Rs.13.59 crore from Rs.12.38 crore. With lower net profit, EPS declined to Rs.1.41 from Rs.2.77 in the last period.
The board of directors has recommended equity dividend of 60 per cent for the year 2014-15. After announcement of lower profit, Suven scrip declined by Rs.20.95 in the afternoon session on BSE to Rs.278.90 as against previous day's closing of Rs.299.85.
For the full year ended March 2015, Suven's net sales improved marginally by 2.1 per cent to Rs.520.86 crore from Rs.510.31 crore in the previous year. Its sales from CRAMS improved by 1.4 per cent to Rs.500 crore from Rs.493 crore and that from Services moved up by 22.6 per cent to Rs.20.69 crore from Rs.16.87 crore. Its R&D expenditure declined by 3.4 per cent to Rs.46.32 crore from Rs.47.95 crore.
Suven's net profit declined sharply by 24.6 per cent to Rs.108.75 crore from Rs.144.16 crore in the previous year. The company provided Rs.11.65 crore as exceptional expenditure in respect of change in provision of depreciation. Similarly, its EBIDTA moved down by 20 per cent to Rs.177.67 crore from Rs.222.09 crore.
The company has raised Rs.200 crore through QIP issue by allotment of 1,04,53,680 equity shares of face value of Rs.1 each at a premium of Rs.190.32 per share. Its equity capital increased to Rs.12.73 crore from Rs.11.68 crore. Its reserves and surplus moved up to Rs.546.59 crore from Rs.252.76 crore in the previous year. For full year ended March 2015, its EPS declined to Rs.9.04 from Rs.12.34 in the last year.